Sugammadex + Neostigmine
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Postoperative Nausea and Vomiting
Conditions
Postoperative Nausea and Vomiting, Respiratory Conditions Due to Other External Agents
Trial Timeline
Feb 12, 2018 → Nov 8, 2018
NCT ID
NCT03276026About Sugammadex + Neostigmine
Sugammadex + Neostigmine is a approved stage product being developed by Merck for Postoperative Nausea and Vomiting. The current trial status is terminated. This product is registered under clinical trial identifier NCT03276026. Target conditions include Postoperative Nausea and Vomiting, Respiratory Conditions Due to Other External Agents.
What happened to similar drugs?
9 of 20 similar drugs in Postoperative Nausea and Vomiting were approved
Approved (9) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04546672 | Approved | Completed |
| NCT03276026 | Approved | Terminated |
| NCT03112993 | Approved | Completed |
| NCT02861131 | Approved | Completed |
| NCT02909439 | Approved | Completed |
| NCT01050543 | Phase 3 | Completed |
| NCT00825812 | Phase 3 | Completed |
| NCT00451217 | Phase 3 | Completed |
| NCT00451100 | Phase 3 | Completed |
Competing Products
20 competing products in Postoperative Nausea and Vomiting